Regulatory News
Wednesday, January 25, 2017
BRIEF-Abbvie initiates phase 2 clinical trial programs for ABBV-8e12
* Abbvie initiates phase 2 clinical trial programs for
ABBV-8e12, an investigational anti-tau antibody, in early
alzheimer's disease and progressive supranuclear palsy
Source text for Eikon:...
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment